en · de · es · fr · pt
thymosin-alpha-1-notes.peptides6608.com › Faq › �ˆ†子身份与天然来源 — Complete Guide

�ˆ†子身份与天然来源 — Complete Guide

By Editorial Desk · published 2025-09-15 · last reviewed 2025-10-16 · Faq

systematic review comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-10-16. Where a claim depends on a specific study, the study is described rather than over-claimed.

分子身份与天然来源

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

20世纪70年代,研究者从胸腺提取物中纯化出多种小肽,Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤,产量低且成分复杂。随着固相肽合成技术成熟,实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上,并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

Molecular Identity Of Thymosin Alpha-1

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Thymosin-alpha-1 at a glance

PropertyValueNotes
化学分类线性肽由28个氨基酸组成
分子量约3108 Da合成版本一致
外观白色至类白色粉末冻干品
溶解度易溶于水微溶于有机溶剂
储存温度-20°C(冻干)溶解后2-8°C

Background, Structure, and Mechanism

Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.

Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.

Related pages on this site

Molecular Structure and Biological Background

Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.

Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.

Research History and Clinical Assessment

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Supporting material

=== Actinium-227 === Actinium-227 is the most stable isotope of actinium, with a half-life of 21.772 years. It mainly (98.62%) undergoes beta decay, but sometimes (1.38%) it will undergo alpha decay instead. 227Ac is a member of the actinium series. It is found only in traces in uranium ores – one tonne of uranium in ore contains about 0.2 milligrams of 227Ac. 227Ac is prepared, in milligram amounts, by the neutron irradiation of 226Ra in a nuclear reactor.

ECL cells synthesize and secrete histamine. These cells are stimulated by the hormones gastrin (not depicted in the adjacent diagram) and pituitary adenylyl cyclase-activating peptide. G cells are stimulated by vagal stimulation through the neurotransmitter gastrin-releasing peptide; this causes the G cells to secrete gastrin, which in turn stimulates ECL cells to release histamine. Note that this circuit is not activated by acetylcholine (ACh), which is of particular importance because the administration of atropine will not block the vagal stimulation of the G cells, as ACh is not the neurotransmitter for these cells. However, ECL cells are activated directly by ACh on M1 receptors from direct vagal innervation leading to histamine release. This pathway will be inhibited by atropine. Gastrin is transferred from a specific type of G cell in the gastric epithelium to the ECL cells by blood. Histamine and gastrin act synergistically as the most important stimulators of hydrochloric acid secretion from parietal cells and stimulators of secretion of pepsinogen from chief cells. The most important inhibitor of the ECL cell is somatostatin from D cells. Enterochromaffin-like cells also produce pancreastatin and probably other peptide hormones and growth factors.

=== Wes: The Meat-Stick Bully === First aired: 24 September 2009 Victim Chris has a problem with a tobacco spittin', hockey playing Texan and self-proclaimed "meat-stick", Wes. Mayhem enlists Tony Bonello to put this bully in his place. He was submitted 4 times and knocked out, but with an illegal head kick. Wes actually managed to knock down Tony Bonello which, apparently, upset the MMA fighter enough for him to break the rules. The kick to the head was hard enough that Wes could not remember where he was, or any of the fight. Because of the illegal kick, the bully received the $5,000 for that round. However, Wes refused it, stating "A knockout's a knockout," and then apologized to Chris by giving the money to him. Mayhem refers to Chris as his favorite victim because he is cute and adorable.

Sources: en.wikipedia.org

Supporting material

== Founding of the State of Israel == The State of Israel was finally established on 14 May 1948 with the Israeli Declaration of Independence. The concept of a national homeland for the Jewish people in the British Mandate of Palestine was enshrined in Israeli national policy and reflected in many of Israel's public and national institutions. The concept was expressed in the Israeli Declaration of Independence on 14 May 1948 and given concrete expression in the Law of Return, passed by the Knesset on 5 July 1950, which declared: "Every Jew has the right to come to this country as an oleh."

=== Indications === Persons with G6PD deficiency are asymptomatic. An attack of acute haemolytic anaemia can appear out of nowhere and can be very severe and life-threatening. Indications of such a sudden attack of favism are dark urine, pallor, jaundice, abdominal pain and in most cases fever.

== History and clinical trials == In the 1970s, Jens Juul Holst and Joel Habener began research on GLP-1, initially in relation to duodenal ulcer disease. They were examining hormones secreted during eating, and testing them on pig pancreases, leading to the discovery of GLP-1's significant effects in 1988. Their work, which later contributed significantly to diabetes and obesity treatments, earned them and Daniel J. Drucker the 2020 Warren Alpert Foundation Prize. Research continued, and in 1993, Michael Nauck managed to infuse GLP-1 into people with type 2 diabetes, stimulating insulin while inhibiting glucagon and bringing blood glucose to normal levels. However, treating diabetes with GLP-1 hormones resulted in significant side effects, leading researchers financed by Novo Nordisk to start looking to develop a suitable compound for therapeutic use. In 1998, a team of researchers at Novo Nordisk led by Lotte Bjerre Knudsen developed liraglutide, a GLP-1 receptor agonist that could be used to treat diabetes. This was followed by the development of semaglutide by a team of researchers at Novo Nordisk, including Jesper Lau, Thomas Kruse, and Paw Bloch.

Sources: en.wikipedia.org

Frequently asked questions

胸腺素α1是激素吗?

它不是经典的内分泌激素,而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现,而非经血液循环作用于远隔器官。

天然来源是什么?

天然胸腺素α1主要从胸腺组织提取,也可在脾脏和淋巴结中检出。目前研究和临床使用的多为化学合成版本,不再依赖动物组织。

它和胸腺素组分5有什么关系?

胸腺素组分5是牛胸腺提取物的粗组分,包含多种肽。胸腺素α1是其中一种被纯化和表征的单一肽,具有明确的28个氨基酸序列。

Is this peptide found naturally in the body?

Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.

Network